Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shares are trading higher Monday, potentially driven by momentum from a late-Friday announcement regarding operational updates. Here's what you need to know.
What To Know: Shortly before the market close on Friday, Tevogen said it's close to finalizing a deal with CD8 Technology to establish a comprehensive, turn-key facility to support both pre-clinical research and GMP manufacturing capabilities. The facility is expected to be staffed by Tevogen, providing necessary infrastructure to advance the company's pipeline.
In connection with the announcement, Tevogen Bio highlighted an active agreement enabling access to a $36 million line of credit, which supports the company's ongoing operations and long-term growth efforts.
Moreover, the company's leadership addressed the company's depressed stock price and reassured investors of Tevogen Bio's focus on sustaining financial stability and shareholder value. Tevogen Bio shares are down more than 87% year-to-date. The stock was trading down close to $1 per share on Friday before surging more than 30% and closing Friday up nearly 10% for the session.
"As we prepare to file our most recent quarterly financials, I want to highlight that Tevogen Bio has the funding it needs to sustain its operations and continue executing our strategy. We remain attentive to enhancing shareholder value, which is always top of mind for our team as we work to drive long-term success," commented Kirti Desai, Tevogen Bio's CFO.
TVGN Price Action: Tevogen Bio shares were up 12.7% at $1.37 at the time of writing, according to Benzinga Pro.
What's Going On With Shopify Stock Monday?
Photo: Pixabay.
Tevogen Bio Holdings Inc. (ナスダック:TVGN)の株は月曜日に上昇して取引されており、これは金曜日の遅い時間に発表された運営アップデートに関する勢いによる可能性があります。知っておくべきことは次の通りです。
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会（ASIC）の管理を受けております（AFSL No. 224663）。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会（ASIC）の管理を受けております（AFSL No. 224663）。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。
Moreover, the company's leadership addressed the company's depressed stock price and reassured investors of Tevogen Bio's focus on sustaining financial stability and shareholder value. Tevogen Bio shares are down more than 87% year-to-date. The stock was trading down close to $1 per share on Friday before surging more than 30% and closing Friday up nearly 10% for the session. 
さらに、同社のリーダーシップは、同社の低迷する株価について言及し、Tevogen Bioが財務の安定性と株主価値を維持することに焦点を当てていることを投資家に安心させました。Tevogen Bioの株は年初来で87%以上下落しています。金曜日に株は1株あたりほぼ1ドル近くで取引されていましたが、その後30%以上急上昇し、金曜日のセッションをほぼ10%上昇して終了しました。 